Virus Filtration Development for Adeno‐Associated Virus‐Based Gene Therapy Products
Biotechnology Journal · 2025
DOI: 10.1002/biot.202400636 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biotechnology Journal, 2025. Verfasst von Fnu Namila und 3 weiteren Autor:innen. Beteiligte Einrichtung: Drug Substance Development, Spark Therapeutics, Inc., Philadelphia, USA. Hauptthemen laut MEDLINE: Dependovirus, Genetic Therapy, Genetic Vectors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
Adeno‐associated virus (AAV) vectors have become a leading platform for gene delivery. A major portion of gene therapy currently in clinical trials are AAV‐based for a wide range of diseases. A commonly used method for AAV production is by mammalian or insect cell culture, with or without added viruses to introduce needed genetic elements for AAV production. There are potential risks of virus contamination from the production cell line, process residuals, or adventitious contamination in the production of biotherapeutics, including AAV‐based gene therapy products; therefore, it is imperative to demonstrate that the drug substance manufacturing process has sufficient capability to clear process‐related or adventitious viruses. In the AAV‐based gene therapy manufacturing process, cell lysis, affinity chromatography, and ion exchange chromatography steps are often effective to inactivate or remove viruses. To increase the viral clearance robustness, virus filtration (VF) is increasingly recommended by regulatory agencies for gene therapy products as a dedicated viral clearance step in the downstream purification process. In the current study, two commercially available virus filters were evaluated in the context of AAV manufacturing. The filter throughput and process yield were assessed under different operational modes. Virus clearance performance was evaluated by spiking in Adenovirus type 5 (Adv‐5) and Simian virus 40 (SV‐40). The viral filters assessed in this study demonstrated manufacturable throughputs, acceptable process yields, and robust virus clearance capabilities for viruses greater than 40 nm.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Drug Substance Development, Spark Therapeutics, Inc., Philadelphia, USA.
ORCID-Profile: Fnu Namila, Tianyi Zhou, Lu Wang, Mi Jin
Zitieren
APA
Namila, F., Zhou, T., Wang, L., & Jin, M. (2025). Virus Filtration Development for Adeno‐Associated Virus‐Based Gene Therapy Products. Biotechnology Journal. https://doi.org/10.1002/biot.202400636
Vancouver
Namila F, Zhou T, Wang L, Jin M. Virus Filtration Development for Adeno‐Associated Virus‐Based Gene Therapy Products. Biotechnology Journal. 2025. doi:10.1002/biot.202400636
BibTeX
@article{Namila2025,
author = {Namila, Fnu and Zhou, Tianyi and Wang, Lu and Jin, Mi},
title = {Virus Filtration Development for Adeno‐Associated Virus‐Based Gene Therapy Products},
journal = {Biotechnology Journal},
year = {2025},
doi = {10.1002/biot.202400636}
}
EUVIMED